Trial Profile

F573 for Injection for the Treatment of Liver Injury/failure : Randomized, Double-blind, Placebo-controlled Phase II a Clinical Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs F 573 (Primary)
Indications Liver failure; Liver injury
Focus Adverse reactions
Sponsors Beijing Continent Pharmaceutical

Most Recent Events

17 Mar 2025 According to Gyre Therapeutics media release, Completion of this Phase 2 clinical trial of F573 is expected by the end of 2026.
26 Mar 2024 According to Gyre Therapeutics media release, Gyre Pharmaceuticals is conducting a randomized, double-blind, placebo-controlled Phase 2 clinical trial in the PRC to assess the safety and efficacy of F573 for injection in the treatment of liver injury/failure.
19 Feb 2024 Planned number of patients changed from 90 to 97.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com